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Abstract
It is accepted that confusion regarding the description of genetic variants occurs when researchers do not use standard no-
menclature. The Human Genome Organization Gene Nomenclature Committee contacted a panel of consultants, all work-
ing on the KAL1 gene, to propose an update of the nomenclature of the gene, as there was a convention in the literature of
using the ‘KAL1’ symbol, when referring to the gene, but using the name ‘anosmin-1’ when referring to the protein. The new
name, ANOS1, reflects protein name and is more transferrable across species.
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Introduction
An analysis of research and review articles published in inter-
national journals has been carried out to briefly summarize
both the well established and the most recent knowledge on the
ANOS1 gene and anosmin-1 physiopathology in Kallmann’s and
other diseases.
This article reports the most relevant information on ANOS1
and its product anosmin-1, from the identification to its new
functions. It addresses a topic of importance to endocrinologists
of reproduction, with indications for a better and correct classi-
fication of the genetic variants of Kallmann’s disease. The au-
thors, together with the panel of consultants, hope that
researchers and the scientific community, overall, will use the
new nomenclature ANOS1 for the gene encoding for anosmin-1
and responsible for the X-linked form of Kallmann syndrome
(KS), and ANOS2P for the pseudogene on the Y chromosome.
The symbol ANOS1 will be propagated to orthologs in vertebrate
species.
The application of a standard genetic nomenclature is fun-
damental to an accurate scientific communication and a correct
classification of disease-related genes. In this regard, the
Human Genome Organization (HUGO) Gene Nomenclature
Committee (HGNC: www.genenames.org) [1] has recently pro-
posed to the community to standardize the nomenclature of
the KAL1 gene to ANOS1. The ANOS1 gene was first described as
responsible for KS, a developmental genetic disease belonging
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to the wide family of congenital idiopathic hypogonadotropic
hypogonadism.
KS was described as a genetic heterogeneous association be-
tween a lack of olfaction/smelling (anosmia) and hypogonado-
tropic hypogonadism, as the cause of sterility [2–4], with a
prevalence estimated from around 1:8000 in men and 1:40 000 in
women [5]. Adult patients typically show normal or low levels of
circulating gonadotropins and low serum gonadal hormone lev-
els because of an impairment of the function of gonadotropin-
releasing hormone (GnRH) system, the master regulators of the
hormonal reproductive axis. The lack of smell results from a de-
velopmental defect of the olfactory bulb (OB) [6].
The olfactory and reproductive dysfunctions may be com-
bined with other defects or satellite symptoms, including renal
agenesis, mirror movement (synkinesis), syndactyly, craniofa-
cial abnormalities, coloboma and sensorineural deafness.
It took until 1989 to get the evidence that the biological de-
fects observed in one 19 week-old KS-affected human fetus
resided in the defective development of the olfactory axons and
the arrest of hypothalamic GnRH neurons in their migration
from the olfactory placode to the hypothalamus [7]; the results
of this pioneering report have been confirmed more later in a 25
week-old KS-affected male fetus and in other fetuses affected
by developmental arrhinencephalic disorders [8].
However, it was at the beginning of the 1990s decade that the
assignment of a syndrome locus on the X chromosome was
made [9], and the detection of a genetic lesion at Xp22.3 led to
the definitive identification of the first KS candidate gene [10,
11]. A clinical severe form of hypogonadism is present in pa-
tients affected by the X-linked form of KS, which includes an ab-
sent or altered pulsatile gonadotropin secretion, low serum
testosterone levels and a lack of puberty; however, the gonado-
tropin response to GnRH stimulation is preserved in these sub-
jects [12]. X-linked KS phenotype is characterized by a severe
anosmia, bimanual synkinesia, bilateral cryptorchidism and
renal agenesis [13]. MRI analysis reveals aplastic or dysplastic OB
and other brain changes associated with mirror movement [14].
The gene causative for the X-linked form of KS was named
Kallmann syndrome 1 sequence (KAL1) [15]. The gene escapes X
inactivation, has a homolog on the Y chromosome (originally
named KALP) and shows an unusual pattern of conservation
across species because it has not been so far identified in mouse
and rat [15]. Other different modes of KS transmission (auto-
somal dominant and recessive) have since been described [8],
among them the autosomal dominant form caused by mutation
of the gene FGFR1, initially defined as KAL2 gene [16].
Interestingly, both KAL1 and FGFR1 have been recently proposed
for noninvasive embryonic diagnosis of KS [17]. The contribu-
tion of FGFR1 to congenital hypopituitarism has been recently
revisited [18]. Of interest, the first report on ANOS1 overexpres-
sion, because of a recessive X-chromosome microduplication,
in humans reveals a phenotype characterized by hyperosmia,
genital anomalies (testicular hydrocele and cryptorchidism),
ectrodactyly and additional symptoms like mild intellectual dis-
ability, unilateral hearing loss, stocky build and facial dysmor-
phism, possibly related to a possible interference with the
FGFR1 signal [19].
ANOS1 loss-of-function mutations are associated with the
X-linked KS phenotype, but they have not so far been linked
with other developmental defects (midline abnormality, cleft
palate) found in other forms of KS [13].
Moreover, in recent years, the identification of a large pro-
portion of oligogenic forms of the disease has changed the
whole view of the genetic basis of KS [20].
The ANOS1 gene is largely conserved from invertebrates to
primates including some rodents (Table 1). It is peculiar to note
that although human ANOS1 gene product has been found to be
functional in mice cells and tissues [21, 22], its immunoreactiv-
ity has been detected in rat tissue, using an antibody for the
human protein, and human and mice share about 99% of genes;
no KAL1 ortholog in mouse and rat has been so far identified
[23], making a more complete genetic analysis of the role of
ANOS1 in biological processes using classical rodent models not
possible.
Anosmin-1
The ANOS1 gene contains 14 exons and encodes for the protein
anosmin-1 whose lack or mutation is responsible for the main
symptoms characterizing the X-linked form of this disease [24].
Anosmin-1 is a 680 amino acid glycoprotein of the extracellular
matrix [25], with a high degree of sequence identity among spe-
cies, that contains: (i) a cysteine-rich region (CR domain), (ii) a
whey acidic protein (WAP)-like domain similar (like serine
protease inhibitors), (iii) four consecutive fibronectin type III do-
mains (FNIII, like many cell-adhesion molecules) and (iv) a
C-terminal region rich in basic histidines and prolines [26]
(Figure 1). The WAP domain is present in protease inhibitors
and was found to play a role in axonogenesis and neuron migra-
tion. FnIII domains are present in proteins involved in cell adhe-
sion, in tyrosine kinases and in phosphatases, implicated in
neuronal migration and in axon guidance. In this sense, along
this sequence, it is noteworthy that there are five potential
heparan sulphate-binding sites as well as six sites for possible
N-glycosylation.
The expression of ANOS1 messenger RNA (mRNA) and
anosmin-1 protein extends from the embryonic development to
adulthood, and it should be remarked that both mRNA and pro-
tein are largely more present in the different structures of the
central nervous system (CNS, including cerebral cortex, OB and
other components of the olfactory system, retina, cerebellum,
spinal cord) than in other body organs and structures (inner ear,
kidney, testis, skin and vascular endothelial cells), and overall
explains the main and satellite symptoms in KS patients (for a
comprehensive review on the subject, see [27]).
Table 1. Orthologs of human KAL1 gene with updated nomenclature
to ANOS1 and similarities in different species
Organism Gene name Human gene
similarity (%)
Chimpanzee ANOS1 97
Cow ANOS1 79
Dog ANOS1 82
Chicken ANOS1 74
Guinea Pig ANOS1 84
Rabbit ANOS1 74
Squirrel Anos1 87
Rat No ANOS1 ortholog
so far identified
–
Mouse No ANOS1 ortholog
so far identified
–
Zebrafish anos1a, anos1b 61
C. elegans kal-1 42
Drosophila Anos1 38
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Although different putative interacting proteins for
anosmin-1 have been described to date, the mechanism of ac-
tion of this protein remains far from completely characterized.
FGFR1, heparan sulphates, syndecan, glypicans, as well as dif-
ferent components of the extracellular matrix (uPA, fibronectin,
laminin, integrin-beta, anosmin-1 itself—in many of these
cases, the activity seems totally independent of FGF2–FGFR1 sig-
naling) are able to interact with anosmin-1 either alone or, occa-
sionally (this is the case of FGFR1 and heparan sulphate),
together and with different results [23, 28–30]. Among them,
FGFR1 is undoubtedly the most studied because mutations in
FGFR1 gene (KAL2) are responsible for the autosomal dominant
form of KS [16]. In total, >60 mutations of ANOS1 have been
described, but clear hot spots have not been identified (Figure 1)
[31]. Most of mutations are deletion, frameshift or nonsense;
missense mutations in the FnIII domains of ANOS1 are among
the most frequent in KS patients, while the real significance of
the mutations in the WAP domain on the biological activity of
anosmin-1 remains far from clear [21, 29, 32]. More details on
the ANOS1 gene mutations underlying KS, including the sug-
gested heterogeneity of effects related to the cell type, their
extracellular environment or the combined interaction with dif-
ferent putative receptors, have been widely reported [23, 31].
More recently, a study carried out in Caenorhabditis elegans re-
vealed that KAL-1/anosmin-1 may mediate neurite branching
by acting as an autocrine cofactor of FGF signaling through a
receptor complex consisting of the nematode orthologs of
fibroblast growth factor receptor and cell adhesion molecule
L1 [33].
Regarding its function in biology, in different in vitro models,
anosmin-1 has been demonstrated to affect cell adhesion, neu-
rite outgrowth and branching [34–36] and cell migration [21],
whereas in in vivo models, it appears to regulate several aspects
of neurogenesis [22], the motility/migration of different neural
cell types during development and, both physiologically and in
pathological scenarios in the adult [28, 30, 37], the outgrowth of
axons and the genesis of axon collaterals [38, 39] as well as in
the differentiation of oligodendrocytes and myelin formation
[40]. Finally, the relevance of locally produced anosmin-1 on
regulating three major morphogens like FGF8, BMP5 and
WNT3a and therefore its crucial role in the formation of the
neural crest has been also shown [41].
Other functions of Anosmin-1
Besides KS, anosmin-1 has been described as relevant in the
pathogenesis of multiple sclerosis, the most frequent primary
demyelinating disease and the most frequent neurological dis-
ease in young adults: the protein is upregulated in the core of
chronic-active and chronic-inactive demyelinating lesions (in
this zone of the lesions, there is no spontaneous remyelination),
maybe produced by astrocytes, but not in the periplaque of the
former type or in active lesions, the only sites where spontan-
eous remyelination by endogenous oligodendrocyte precursor
cells occurs [37]. Also in samples from human cerebral cortices
with multiple sclerosis, anosmin-1 is present in 13–14% of the
nude axons crossing demyelinated lesions, but not in their peri-
plaques or in the normal appearing white matter [37]. It is ex-
tremely interesting that endogenous oligodendrocyte precursor
cells effectively recruited toward demyelinating lesions are
mainly positive for FGFR1, which suggests that this lack of po-
tential remyelinating cells would be because of anosmin-1
antagonizing the FGF2 motogenic effect [28, 37] (this scenario
has been described more extensively by de Castro and cow-
orkers [23, 42]). Indeed, the relationship between KS and demye-
lination/multiple sclerosis remains to be fully addressed after
recent reports [43, 44, 45]. The real/direct contribution of ANOS1
gene to septo-optic dysplasia and deafness has been recently
reevaluated together with the availability of new diagnostic
tools [46–48].
Anosmin-1 protein also exerts functions outside the CNS: it
modulates the response to immunoglobulin therapy in derma-
tomiositis [49] and regulates the density of nerve terminals in
the epidermis affected by atopic dermatitis [50]. More recently,
it has been shown that is concomitant SOX10 mutation the real
cause of skin/hair/iris hypopigmentation [48].
Finally, ANOS1 has been involved in migration and metasta-
sis of cancer cells; in particular, its expression was found modi-
fied in several tumors including brain, ovarian, colorectal,
hepatocellular and oral squamous cancer [30, 51–55], where it
may play a role as a possible modulator of the reactivation of
developmental signal pathways, and therefore proposed as
diagnostic or prognostic tool. In this regard, recently, it has been
proposed that while the serum levels of anosmin-1 would be a
good biomarker for gastric cancer prognosis and treatment
stratification of patients [56], ANOS1 may be a tumor suppressor
for hepatocellular cancer [55].
The change of nomenclature
The scientific community has previously used KAL1, KAL-1 and
even ANOS-1 or ANOS1 (both, with or without hyphen, either in
capital letters or not) to refer to the same gene, that encodes
anosmin-1. In accordance with the suggestion of HGNC,
who supported and encouraged us to write this position state-
ment, we and the other researchers forming the group of con-
sultants recruited by HGNC (see Acknowledgements) agree here
to adopt the gene name anosmin1 (without hyphenation),
encoding for anosmin-1 protein, with the approved symbol
ANOS1 (Table 2).
The symbol ‘KAL’ was first approved in 1986 by the HGNC to
represent the KS phenotype rather than a specific gene. This
was later updated from KAL to KAL1 to distinguish it from the
distinct form of KS known as KAL2. The causative gene for the
X-linked form of KS was identified by two separate groups in
1991 as KALIG-1 for ‘Kallmann’s syndrome interval gene 1’ [10]
and as ADMLX for ‘adhesion molecule-like from the X
Figure 1. Structure of ANOS1 gene and of anosmin-1 protein. Schematic repre-
sentation of the ANOS1 gene location on the short arm of X chromosome, of
anosmin-1 mRNA and protein structures and mutations. The number on the
mRNA structure indicates the exons covering the ORF of the protein anosmin-1;
shaded area indicates the exons involved in the coding of the different protein
domains. The position of the CR domain, the WAP-like domain, the four FNIII re-
peats and the histidine-rich domain of anosmin-1 are also indicated. Main exon
deletions are shown with black lines, and point mutations are indicated by the
arrows; the size of the arrows indicates approximately the frequency of the
identified mutations (adapted from [31]).
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chromosome’ [11]. As neither symbol fitted with HGNC guide-
lines, the symbol KAL1 was retained for the cloned gene.
The first study on the protein encoded by KAL1 named this
protein ‘anosmin-1’ to reflect the loss of smell, or anosmia, in
patients with KS [24]. The name anosmin-1 grew in popularity
over the years, and it became the convention to refer to the
gene as KAL1 and the protein as anosmin-1. The protein name
has been used for different species such as zebrafish [35], tam-
mar wallaby [31] and Asian musk shrew [57].
In early 2015, the HGNC proposed updating the gene nomen-
clature to be in line with the protein name because this is more
transferrable across species and avoids any confusion between
‘KAL1’ and other genes that cause forms of KS. Additionally, the
name ‘anosmin’ is indicative of function since the lack of sense
of smell in KS is because of the role of the protein in axonal out-
growth in the olfactory system. This nomenclature scheme may
also be readily adapted to incorporate additional genes encod-
ing other anosmins that would be eventually identified in the
future. The symbol Anos1 [35] had already been published as an
abbreviation for ‘anosmin-1’, and as this symbol is unique, the
HGNC proposed the symbol ANOS1 and named anosmin1 for
the gene. Hyphens were omitted to follow the conventions of
gene nomenclature. The HGNC contacted researchers who had
previously published on KAL1, and there was community sup-
port for the change.
The change in nomenclature of KAL1 resulted in a concord-
ant change for the inactive homolog, which is present on the Y
chromosome. This gene was first reported as a pseudogene be-
cause of frameshift and premature stop codons and named
KALP [15]. Surrounding gene order and theories on Y chromo-
some evolution [58, 59] suggest that KALP has degraded in situ
rather than being a duplication of ANOS1. According to annota-
tion by the HAVANA group [60], this pseudogene is still tran-
scribed. Therefore, KALP has been renamed as ANOS2P for
‘anosmin2, pseudogene’ to reflect its status as a degraded
homolog of ANOS1 and not as a duplicated pseudogene of
ANOS1 (which would have been given the symbol format
ANOS1P1).
We hope that interested researchers and the scientific com-
munity, overall, will use the new nomenclature ANOS1 for
the gene encoding for anosmin-1 and responsible for the
X-linked form of KS, and ANOS2P for the pseudogene on the
Y chromosome. The symbol ANOS1 will be propagated to
orthologs in vertebrate species, and we request that re-
searchers working on other species will also use the updated
symbols.
Key Points
• A different nomenclature is used to define Kallmann
syndrome 1 gene (KAL1) and its proteic product (anos-
min-1).
• The most recent knowledge on the KAL1 gene and
anosmin-1 confirms their involvement in the physio-
pathology of Kallmann’s disease but also in other
diseases.
• The HUGO Gene Nomenclature Committee (HGNC)
with a panel of consultants propose an update of the
nomenclature of the KAL1 gene in anosmin1 (ANOS1)
and ANOS2P for the pseudogene present on the Y
chromosome.
• This nomenclature scheme may also be readily
adapted to incorporate additional genes encoding
other anosmins that would be eventually identified in
the future.
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